

1 DMT1 knockout abolishes ferroptosis induced mitochondrial dysfunction in *C. elegans*
2 amyloid β proteotoxicity

3

4 Wilson Peng¹, Kaitlin B Chung¹, B Paige Lawrence², M Kerry O'Banion³, Robert T
5 Dirksen¹, Andrew P Wojtovich^{1,4}, John O Onukwufor^{1,2*}

6 ¹Department of Pharmacology and Physiology, University of Rochester School of
7 Medicine and Dentistry, Rochester NY, 14642 USA

8 ²Department of Environmental Medicine, University of Rochester School of Medicine
9 and Dentistry, Rochester, NY, USA 14642

10 ³Department of Neuroscience, Del Monte Institute for Neuroscience, University of
11 Rochester School of Medicine and Dentistry, Rochester, NY, USA 14642

12 ⁴Department of Anesthesiology and Perioperative Medicine, University of Rochester
13 School of Medicine and Dentistry, Rochester NY, 14642 USA

14 *Corresponding author

15 John O. Onukwufor

16 Email: john_onukwufor@urmc.rochester.edu

17 **Highlights**

- 18 1. Energetic imbalance is an early event in iron-induced loss of neuronal function
- 19 2. Neuronal A β increases susceptibility to ferroptosis mediated oxidative damage
- 20 3. Divalent metal transporter 1 knockout protects against iron-induced oxidative
- 21 damage and ferroptosis

22

23 **Abstract**

24 Iron is critical for neuronal activity and metabolism, and iron dysregulation alters these
25 functions in age-related neurodegenerative disorders, such as Alzheimer's disease (AD).
26 AD is a chronic neurodegenerative disease characterized by progressive neuronal
27 dysfunction, memory loss and decreased cognitive function. AD patients exhibit elevated
28 iron levels in the brain compared to age-matched non-AD individuals. However, the
29 degree to which iron overload contributes to AD pathogenesis is unclear. Here, we
30 evaluated the involvement of ferroptosis, an iron-dependent cell death process, in
31 mediating AD-like pathologies in *C. elegans*. Results showed that iron accumulation
32 occurred prior to the loss of neuronal function as worms age. In addition, energetic
33 imbalance was an early event in iron-induced loss of neuronal function. Furthermore, the
34 loss of neuronal function was, in part, due to increased mitochondrial reactive oxygen
35 species mediated oxidative damage, ultimately resulting in ferroptotic cell death. The
36 mitochondrial redox environment and ferroptosis were modulated by pharmacologic
37 processes that exacerbate or abolish iron accumulation both in wild-type worms and
38 worms with increased levels of neuronal amyloid beta ($A\beta$). However, neuronal $A\beta$ worms
39 were more sensitive to ferroptosis-mediated neuronal loss, and this increased toxicity was
40 ameliorated by limiting the uptake of ferrous iron through knockout of divalent metal
41 transporter 1 (DMT1). In addition, DMT1 knockout completely suppressed phenotypic
42 measures of $A\beta$ toxicity with age. Overall, our findings suggest that iron-induced
43 ferroptosis alters the mitochondrial redox environment to drive oxidative damage when
44 neuronal $A\beta$ is overexpressed. DMT1 knockout abolishes neuronal $A\beta$ -associated
45 pathologies by reducing neuronal iron uptake.

46 **Keywords:** *Oxidative stress, Ferroptosis, Bioenergetics, A β proteotoxicity, Divalent metal*
47 *transporter 1*

48

49 **1. Introduction**

50 Iron is essential for cellular function, where its tight regulation aids in
51 neurotransmitter biosynthesis, myelination, and energy homeostasis[1-3]. Cellular iron
52 levels are controlled by iron regulatory proteins. These include divalent metal transporter
53 1 (DMT1), which facilitates cytosolic ferrous iron uptake, and ferritin, which enables the
54 storage of ferrous iron in the form of ferric iron, and ferroportin, which exports ferrous iron
55 out of the cytosolic environment[3, 4]. Free ferrous iron not stored or exported from the
56 cell is utilized for a variety of cellular functions. Mitochondria use ferrous iron for heme
57 biosynthesis, iron-sulfur cluster formation and mitochondrial electron transport chain
58 (ETC) activity for energy production[3, 5, 6]. However, as organisms age, the efficiency
59 of iron regulatory proteins to sequester and control cytosolic free ferrous iron declines,
60 leading to excess free ferrous iron levels that impair mitochondrial function[7, 8].

61 The impairment of mitochondrial activity by excess ferrous iron results in lower
62 cellular ATP production and higher mitochondrial reactive oxygen species (ROS)
63 production[5, 9]. Mitochondrial ROS, when produced in small quantities, are important for
64 cellular signaling[10-12]. However, large increases in mitochondrial ROS, as occurs with
65 iron toxicity, trigger oxidative stress and damage to membrane proteins and lipids[9, 11].
66 Mitochondrial ROS can also react with ferrous iron to produce potent reactive free radicals
67 that cause cellular death by ferroptosis[3]. Ferroptosis is an iron-dependent programmed
68 cell death mechanism mediated by ROS induced lipid peroxidation[13, 14]. Ferroptosis is

69 associated with many age-related disorders, such as Alzheimer's disease (AD)[3, 6].
70 However, the underlying cellular and molecular mechanisms, as well as the degree to
71 which iron-induced ferroptosis contributes to AD pathogenesis remains unknown.

72 Model organisms offer a tractable system to interrogate causal relationships in
73 order to fine-tune our mechanistic understanding of how iron dysregulation contributes to
74 AD pathogenesis. *C. elegans* is an excellent model to investigate the cellular and
75 molecular mechanisms of mitochondrial iron dysregulation in AD[15, 16]. In *C. elegans*,
76 movement disorders correlate with a decline in neural function, while swimming rates
77 provide a reliable read out of energetic output. Both of these phenotypes correlates with
78 the observed pathology in AD patients[17, 18].

79 Therefore, we used wild-type *C. elegans*, as well as *C. elegans* overexpressing
80 neuronal A β , to elucidate how iron dysregulation contributes to altered physiology. We
81 found that energetic imbalance measured by impaired swimming rate and mitochondrial
82 dysfunction represent early events in iron-induced toxicity. Iron toxicity was facilitated by
83 ROS induced oxidative damage that promotes ferroptosis. Pharmacologic and genetic
84 methods of inhibiting or promoting ferroptosis either exacerbated or abolished,
85 respectively, ferroptotic pathologies. Furthermore, worms with over expression of
86 neuronal A β were more sensitive to iron induced toxicity than age-matched wild-type
87 worms and knockout of DMT1 mitigated this enhanced iron-induced pathology of
88 neuronal A β . These findings suggest that enhanced iron toxicity promotes A β pathology
89 and that iron regulatory proteins such as DMT1 represent potential therapeutic targets to
90 mitigate A β -mediated toxicity.

92 **2. Materials and Methods**

93 *Worm maintenance and strains*

94 *C. elegans* were maintained on OP50 bacterial lawns on nematode growth media (NGM).
95 The following strains were used in this investigation: wildtype [N2]; CL2355 [*smg-1(cc546)*
96 *dvls50 I*]; RB1074 [*smf-3(ok1035) IV*], and OJO1 [*smg-1(cc546) dvls50 I; smf-3(ok1035)*
97 *IV*]. CL2355 and OJO1 were maintained at 16°C, and all other strains were maintained at
98 20°C. All the strains used in this study, with the exception of the OJO1 strain generated
99 in house, were provided through the *Caenorhabditis* Genetics Center (CGC).

100 *Mitochondrial isolation*

101 Mitochondria were isolated by differential centrifugation as previously described[12]. In
102 brief, approximately 0.25 million synchronized L4 worms were grown on HB101 with iron
103 (0 or 35 µM) for 3 days. Worms were then rinsed with M9 media (22 mM KH₂PO₄, 42 mM
104 Na₂HPO₄, 86 mM NaCl, 1 mM MgSO₄, pH 7) before transferring to mitochondrial isolation
105 media (220 mM mannitol, 70 mM sucrose, 5 mM MOPS, 2 mM EGTA, pH 7.3 at 4°C).
106 Using pure sea sand in an ice-cold mortar, worms were crushed followed by a Dounce
107 homogenization. The homogenate was then passed through a series of differential
108 centrifugations using mitochondrial respiratory media (220 mM mannitol, 70 mM sucrose,
109 5 mM MOPS, 2 mM EGTA, 0.04% BSA, pH 7.3 at 4°C) to enrich the mitochondrial
110 preparation. The protein concentration of the mitochondrial preparation was determined
111 using the Folin-phenol method. Mitochondrial respiration and superoxide measurements
112 were conducted using freshly isolated mitochondria. Mitochondrial enzyme activity was
113 conducted using frozen mitochondria within 2 weeks of isolation.

114 *Mitochondrial respiration*

115 Freshly isolated mitochondria were used to measure mitochondrial respiration using a
116 Clark-type O₂ electrode (Hansatech Instruments, UK) as described previously[12]. In
117 brief, after calibration of the electrode, mitochondria (1 mg/ml) suspended in mitochondrial
118 respiration buffer (120 mM KCl, 25 mM sucrose, 5 mM MgCl₂, 5 mM KH₂PO₄, 1 mM
119 EGTA, 10 mM HEPES pH 7.3) were loaded in the chamber. Mitochondrial complex I
120 powered respiration was measured using complex I-linked substrates, 2.5 mM malate
121 plus 5 mM glutamate. The addition of ADP (0.4 mM) was used to drive state 3 respiration
122 followed by the addition of oligomycin (1 µg/ml) to generate state 4 respiration. All
123 substrates were added to the chamber via a syringe port.

124 *Mitochondrial enzyme activity*

125 Complex I and citrate synthase activities were assessed by spectrophotometric methods
126 following permeabilization of isolated mitochondria (1 mg/ml) with three bouts of freeze-
127 thaw[12]. Citrate synthase activity was measured as the rate of DTNB-coenzyme A
128 formation with an extinction coefficient of 13600 M⁻¹ at 412 nm. Complex I activity was
129 determined as the rotenone-sensitive rate of NADH oxidation with an extinction coefficient
130 of 6180 M⁻¹ at 340 nm.

131 *Mitochondrial superoxide measurement*

132 Superoxide production from freshly isolated mitochondria was assessed using 2-
133 hydroxyethidium (2-OHE⁺)[19]. In brief, proteins were precipitated using 200 mM
134 HClO₄/MeOH and removed via centrifugation followed by the addition to the supernatant
135 of an equal volume of phosphate buffer (1 M, pH 2.6). Samples were then filtered and

136 separated using a polar-RP column (Phenomenex, 150 x 2 mm; 4 μ m) on an HPLC
137 (Shimadzu) with fluorescence detection (RF-20A). Prior to sample analysis, a standard
138 curve was generated using purified 2-OHE⁺. The HPLC protocol included mobile phase
139 A (A: 10% ACN, 0.1 % TFA) and mobile phase B (60% ACN, 0.1 % TFA) consisting of
140 the following gradient: 0 min, 40% B, 5 min, 40% B; 25 min, 100% B; 30 min, 100% B; 35
141 min 40% B; 40 min, 40% B. Samples were quantified using Lab Solutions (Shimadzu).

142 *Worm paralysis assessment*

143 Synchronized L4 worms were individually transferred to a seeded plate containing iron or
144 drug every 24 h until the end of the trial (duration of trials indicated in respective figures).
145 Paralysis, defined as the inability to move upon mechanical stimulation, was scored every
146 24 h[7].

147 *Worm swimming rate*

148 Synchronized L4 worms were individually transferred to a seeded plate containing iron or
149 drug every 24 h until the end of the trial (duration of trials indicated in respective figures).
150 Non-paralyzed worms were then individually transferred to an unseeded plate containing
151 100 μ l of M9. An acclimatization period of 30 s was included before the assessment of
152 swimming rate calculated over 15 s.

153 *Lipid peroxidation measurement*

154 *In vivo* quantification of lipid peroxidation in individual anesthetized live worms was
155 performed using the BODIPY 581/591 C11[20]. The degree of lipid ROS production was
156 assessed from a shift in BODIPY 581/591 C11 fluorescence emission peak from 590 to

157 510 nm due to the oxidation of the polyunsaturated butadienyl portion of C11-
158 BODIPY[20].

159 *Confocal imaging*

160 Synchronized L4 worms were grown on a plate containing iron (0 or 35 μ M) for 5 days.
161 Worms were then transferred to a seeded plate containing 1.25 μ M BODIPY 581/591 C11
162 for 60 min and then anesthetized on a 2% agarose pad containing 0.1% tetramisole.
163 Worms were imaged using a Nikon AXR confocal microscope equipped with a 40x water
164 objective. All imaged data were analyzed using ImageJ software.

165 *Elemental analyses*

166 Synchronized L4 worms (0.25 million) were transferred to a seeded plate containing iron
167 (0 or 35 μ M) for 3 days. For whole worm elemental analysis, worms were harvested by
168 first washing in M9 media with the worm pellet collected via centrifugation and then
169 resuspended in 1 mL M9 volume. For mitochondrial elemental analysis, mitochondria
170 were isolated (see mitochondrial isolation procedure) and then suspended in
171 mitochondrial buffer. Whole worm and mitochondrial, samples were weighed before
172 digestion. To digest samples, 1mL 69 % HNO₃ and 0.5mL HCl (36%) was added at 100°C
173 for 60 min. Following digestion, samples were cooled, and double deionized water was
174 added up to 10 ml total volume. Samples were analyzed using the following detection
175 limits in ppb (ng/ml): Fe 0.123, Cu 0.0009, Zn 0.0241, Mn 0.00136, and Ca 3.688.
176 Samples were analyzed with ICP-Mass Spectrometry (Perkin Elmer 2000C) and data
177 were normalized to the initial weight of the samples in grams.

178 *Statistical analyses*

179 All statistical analyses were performed using GraphPad™ Prism v10 (GraphPad
180 Software, San Diego, CA, USA). Data were first subjected to normality and homogeneity
181 variance testing. All data in this study passed the test. Data were then analyzed using
182 either an unpaired, two-tailed student's t-test, or one or two-way ANOVA with post hoc
183 multiple comparison correction. Means were considered significantly different when the
184 p-value was < 0.05.

185

186 **3. Results**

187 **3A. Iron toxicity impairs worm physiologic function.**

188 Previous studies found that iron toxicity increases worm paralysis with age[7].
189 Here, we confirmed these findings and established an effective concentration of iron that
190 produced a 50% increase in paralysis after 10 days of exposure at 20°C (Fig. 1A and B).
191 Using 35 µM iron, the lowest effective concentration observed at day 6 at 20°C (Fig. 1B),
192 we determined the impact of iron exposure on two key physiological readouts of neuronal
193 function at 25°C: 1) paralysis and 2) energetic output assessed from swimming rate.
194 These analyses revealed an age-dependent increase in paralysis with a marked
195 difference between control and iron treated worms starting at day 3 of iron exposure (Fig.
196 1D). In contrast, a significant reduction in swimming rate was observed as early as one
197 day after iron exposure (Fig. 1E), consistent with changes in swimming rate being a more
198 sensitive index of iron toxicity onset. These results suggest that energetic failure and
199 reduced neuronal function represent likely downstream events of iron toxicity that initially
200 lead to reduced swimming rate, and eventually, paralysis.

201 Iron toxicity could be mediated by lipid peroxidation. Therefore, we measured
202 whole worm lipid peroxidation in both control and iron-treated worms using BODIPY C11,
203 a probe used to assess lipid oxidization mediated by ferrous iron[20]. Iron-treated worms
204 exhibited higher levels of oxidized lipids relative to non-treated age-matched worms (Fig.
205 1F&G), potentially due to increased iron overload. To directly test this idea, we used ICP-
206 MS to quantify total iron load in control and iron-treated worms. A significant increase in
207 total iron content was observed in iron-treated worms (Fig. 1H), consistent with iron
208 exposure leading to iron overload and toxicity. To further confirm this connection, we
209 tested the ability of exposure to a pharmacologic iron chelator (deferoxamine or DFO) to
210 reverse the effects of iron[21]. These studies revealed that DFO exposure prevented both
211 iron mediated worm paralysis (Fig. 1I) and reduced swimming rate (Fig. 1J). However,
212 DFO does not discriminate between ferrous and ferric iron. In order to determine the iron
213 species that is responsible for altered physiologic processes, we used genetic worms
214 deficient in divalent metal transporter 1 (DMT1 [*smf-3*]), which specifically facilitates
215 ferrous iron uptake[3, 22-24]. We hypothesized that *smf-3*-deficient worms will exhibit
216 reduced ferrous iron uptake, and thus, reduced iron-dependent toxicity. Consistent with
217 these expectations, *smf-3* mutant worms lacked iron dependent paralysis (Fig. 1K) and
218 swimming rate not different from that of non-paralyzed worms (Fig. 1L). These results
219 indicate that cytosolic ferrous iron is primarily responsible for the observed iron-
220 dependent toxicity.

221 **3B. Mitochondrial bioenergetic dysfunction is an early event of iron toxicity.**

222 We found that a significant reduction in swimming rate occurred prior to paralysis
223 (Fig 1D & E). Mitochondria supply the bulk of energy needed for cellular function [11, 25,

224 26]. Therefore, reduced energetic activity could in part be due to an effect of iron on
225 mitochondrial ATP production. To test this hypothesis, we treated worms with and without
226 iron for 3 days, which was the shortest time sufficient to significantly impact mobility (Fig.
227 1D), but well after impairment of swimming rate (Fig. 1E). Under these conditions,
228 maximum state 3 respiration was significantly reduced (Fig. 2A) in the absence of an
229 effect on state 4 respiration (Fig. 2B), thus resulting in reduced respiratory control ratio
230 (RCR), which is a measure of mitochondrial ATP production (Fig. 2C). Therefore, this
231 iron-dependent reduction in RCR translates to reduced ATP output at a time when worm
232 swimming rate is reduced, and paralysis is increased. We also found that complex I
233 enzyme activity (Fig. 2D) and citrate synthase activity (Fig. 2E) were also significantly
234 reduced in mitochondria isolated from iron-treated worms compared to control worms.
235 Prior studies reported that iron-induced toxicity is mediated in part through increases in
236 ROS production[27, 28]. Therefore, we tested if iron-mediated inhibition of mitochondrial
237 respiratory function resulted in increased mitochondrial ROS generation by monitoring
238 superoxide production with DHE-HPLC[12, 19, 29]. We confirmed increased ROS
239 generation in isolated mitochondria from iron-treated worms compared to that observed
240 for control worms (Fig. 2F). These findings are consistent with iron-induced toxicity
241 resulting in both an inhibition of mitochondrial respiration and an increase in mitochondrial
242 ROS production. High levels of mitochondrial ROS cause oxidative damage of membrane
243 lipid in the form of increased lipid peroxidation (Fig. 1F&G). Having observed impaired
244 mitochondrial bioenergetic function, increased mitochondrial ROS production, and
245 enhanced lipid peroxidation in iron-treated worms, we tested if these effects are due to
246 increased accumulation of mitochondrial ferrous iron. We first measured mitochondrial

247 iron content in control and iron-treated WT and *smf-3* mutant worms. Mitochondrial iron
248 (Fig. 2G) and Ca^{2+} (Fig. 2H) content were significantly higher in iron treated WT worms
249 compared to iron treated *smf-3* worms. Since DMT1 (*smf-3*) also facilitates uptake of
250 other divalent metals[23, 24, 30], we also assessed the impact of *smf-3* mutant on
251 mitochondria Cu^{2+} , Mn^{2+} and Zn^{2+} content. While *smf-3* mutant also significantly reduced
252 the mitochondrial content of these divalent metals as expected, mitochondrial levels of
253 these metals were not further impacted by iron exposure (Fig. 2I-K). Overall, the results
254 suggest that ferrous iron toxicity results in mitochondrial dysfunction characterized by
255 reduced aerobic ATP production coupled with increased mitochondrial iron and Ca^{2+}
256 content, ROS production, and lipid peroxidation.

257 **3C. Redox modulation of iron induced oxidative damage.**

258 The above results suggest that iron-induced mitochondrial dysfunction results in
259 increased ROS production and oxidative damage. Thus, reducing or enhancing
260 mitochondrial ROS levels should mitigate or exacerbate, respectively, iron mediated
261 toxicity. Indeed, iron-induced paralysis was decreased and swimming rate was increased
262 following treatment with a mitochondrial-targeted antioxidant (Mito-TEMPO) that traps
263 superoxide[12, 31, 32] (Fig. 3A-C). These findings are consistent with iron-induced
264 mitochondrial toxicity resulting from an increase in mitochondrial superoxide levels (Fig.
265 2F). Superoxide is rapidly dismutated through both non-enzymatic and enzymatic
266 (superoxide dismutase or SOD) means[12]. Manganese (III) Porphyrin (Mn(III)PyP) is an
267 SOD mimetic that converts superoxide to H_2O_2 [12, 33]. Thus, Mn(III)PyP increases the
268 flux rate of conversion of superoxide to H_2O_2 , thereby increasing levels of mitochondrial
269 H_2O_2 . Mn(III)PyP exacerbated iron-induced paralysis and reduced swimming rate (Fig.

270 3D-F), consistent with toxic effects of increased levels of H₂O₂. These results suggest
271 that the species of ROS responsible for the iron mediated toxicity is H₂O₂ (and/or an H₂O₂
272 byproduct like hydroxyl radical). Thus, reducing H₂O₂ should ameliorate iron-induced
273 toxicity. To test this hypothesis, we used EUK 134, an SOD and catalase mimetic[12, 33,
274 34], that rapidly converts superoxide to H₂O₂ and then water. Treatment with EUK 134
275 prevented iron-induced worm paralysis and normalized swimming rate (Fig. 3G-I). Similar
276 results were observed by increasing glutathione levels with N-acetyl cysteine (NAC) (Fig.
277 3J-L). Overall, results in Fig. 3 indicate that the mitochondrial redox environment is a key
278 driver of iron-induced toxicity and that H₂O₂ (or its byproducts) is the ROS responsible for
279 iron mediated oxidative damage.

280 **3D. Ferroptosis mediates iron induced oxidative damage.**

281 Our findings that iron-induced toxicity causes increased levels of ROS (Fig. 2F)
282 and lipid peroxidation (Fig. 1F&G) are consistent with a potential role for ferroptosis, or
283 iron-induced cell death through ROS mediated lipid peroxidation[3, 13]. Therefore, we
284 used canonical ferroptosis modulators (Ferrostatin-1 and RSL3) to assess the
285 involvement of ferroptosis in the observed iron-induced toxicity. Ferrostatin-1 (Fer-1), a
286 small molecule that inhibits lipid peroxidation by scavenging alkoxyl radicals (Fig. 4A),
287 which subsequently leads to reduction in ferroptosis[3, 35-37], abolished both the iron
288 mediated increase in paralysis (Fig. 4B) and decrease in swimming rate (Fig. 4C),
289 consistent with a role for ferroptosis. To more critically assess the role of ferroptosis, we
290 used RSL3, a potent inhibitor of GPX4[3, 38], a selenoenzyme with phospholipid
291 hydroperoxidase activity that converts PUFA-OOH to PUFA-OH (Fig. 4A), thus
292 neutralizing phospholipid oxidative damage[3, 39, 40]. Unlike the mammalian GPX4, C.

293 *C. elegans gpx1* does not contain selenium, but possesses phospholipid hydroperoxidase
294 activity like the mammalian GPX4[41, 42]. In addition, not all mammalian selenium
295 containing glutathione peroxidases possess phospholipid hydroperoxidase activity[43].
296 Thus, GPX4 PUFA oxidation activity could be mediated through phospholipid
297 hydroperoxidase. We tested if the *C. elegans* glutathione peroxidase (*gpx1*) exhibits
298 phospholipid hydroperoxidase activity in response to RSL3 as is observed for mammalian
299 GPX4 [3, 39, 40]. RSL3 alone induced paralysis (Fig. 4D) and reduced swimming rates
300 of non-paralyzed worms (Fig. 4E). Further, this RSL3 exacerbation of iron-induced toxicity
301 was abolished by Fer-1 (Fig. 4D & E). Taken together, these data suggest the involvement
302 of ferroptosis in iron mediated pathology and support the idea that iron-induced toxicity is
303 mitigated by interventions that inhibit ferroptosis.

304 **3E. Worms expressing neuronal A β exhibit an enhanced ROS- and ferroptosis-** 305 **dependent phenotype.**

306 In *C. elegans*, movement disorder (i.e., paralysis) is a readout for decline in
307 neuronal function, which is similarly associated with most neurodegenerative disorders
308 including AD[17, 44]. To investigate the impact of iron toxicity on worm models of AD, we
309 exposed WT and pan-neuronal A β worms (worms expressing human amyloid beta in all
310 neurons)[44] to iron. Neuronal A β worms exhibited greater paralysis and slower
311 swimming rates compared to WT worms under both control conditions and following
312 exposure to 35 μ M iron (Fig. 5A & B). The enhanced control, as well as iron induced,
313 paralysis and reduced swimming rate of neuronal A β worms were all blocked by treatment
314 with MitoTempo, EUK 134, and NAC, but further enhanced by Mn(III)PyP (Fig. 5C & D).
315 Next, we probed the impact of ferroptosis modulators on the enhanced paralysis and

316 reduced swimming rate phenotype of neuronal A β worms. Similar to that observed for
317 modulators of ROS, activator of ferroptosis (RSL3) potentiated, while a ferroptosis
318 inhibitor (Fer-1) reduced, the enhanced paralysis/swimming rate phenotype of neuronal
319 A β worms (Fig. 5E & F). These results indicate that ferroptosis plays an important role in
320 the increased paralysis and reduced swimming rate of neuronal A β worms, thus
321 supporting the notion that ferroptosis represents a potential target for AD intervention.

322 **3F. Neuronal A β worms exhibit enhanced DMT1-dependent iron sensitivity.**

323 To test if neuronal A β worms are more sensitive to iron toxicity, we exposed worms
324 to 8.75 μ M iron, a concentration of iron that is not toxic to WT worms. We found that while
325 exposure for 5 days to 8.75 μ M iron had no effect on WT worms, neuronal A β worm
326 paralysis was increased, and the swimming rate of non-paralyzed worms was reduced
327 (Fig. 6A & B). Importantly, total worm iron accumulation under these conditions was not
328 different between WT and neuronal A β worms (Fig. 6C), suggesting that both WT and
329 neuronal A β worms exhibited a similar tissue iron burden. Together, these data indicate
330 that neuronal A β worms are more sensitive to iron toxicity relative to WT worms. We then
331 tested if knockout of DMT1 (*smf-3*), which prevented iron-induced toxicity in WT worms,
332 prevented the enhanced basal and iron-induced phenotype of neuronal A β worms. DMT1
333 (*smf-3*) mutant significantly reduced paralysis and increased swimming rate of neuronal
334 A β worms under control conditions and also reduced the degree of iron-induced paralysis
335 and swimming rate of these worms (Fig. 6D & E). Importantly, *smf-3* knockout not only
336 significantly reduced the effects of A β overexpression on work activity (i.e., swimming
337 rate), it restored these measures in A β worms to WT levels. Overall, results in Fig. 6
338 demonstrate that genetic disruption of DMT1 (*smf-3*) function mitigates both basal and

339 iron-induced pathologies of neuronal A β worms, and thus, represent a new potential
340 therapeutic target for AD.

341

342 **4. Discussion**

343 As organisms age, the capacity of iron regulatory proteins to properly sequester
344 and control cellular iron weakens resulting in age-related pathologies that contribute to
345 neurodegeneration such as that observed in AD[3, 7, 8]. Here we document a similar
346 observation in *C. elegans*, wherein iron pathology is further exacerbated by neuronal A β .
347 Thus, regulation of cellular iron levels is a critical step in iron-dependent pathologies. Our
348 study focused on two related phenotypes (swimming rate and paralysis) with distinct iron
349 pathology. For example, paralysis (an inability to move) correlates with a decline in
350 neuronal function. We demonstrated that enhanced iron accumulation occurs prior to
351 progressive paralysis, which mirrors the loss of neuronal function in AD that worsens with
352 age[45, 46]. In contrast to paralysis, swimming rate reflects energetic output and reduced
353 swimming rate occurs earlier than loss of neuronal function (paralysis) in WT worms.
354 Reduced swimming rate could also be due to a partial reduction in neuronal function while
355 paralysis reflects progression to complete loss of neuronal function. A decrease in
356 mitochondrial energy production is a likely explanation for the observed iron-induced
357 reduction in swimming rate. Therefore, therapies designed to target mitochondrial iron
358 could alleviate this decline in mitochondrial function. Yet the underlying molecular
359 mechanisms of mitochondrial iron toxicity in AD remain elusive. We propose that ferrous
360 iron inhibition of mitochondrial respiration results in increased mitochondrial ROS

361 generation that ultimately leads to modifications of ETC proteins and increased oxidative
362 damage (e.g., lipid peroxidation).

363 We found that ferrous iron-induced mitochondrial dysfunction drives an increase
364 in oxidative damage in both WT and neuronal A β worms. Others similarly reported that
365 iron exposure promotes oxidative damage[47, 48]. However, precisely how ferrous iron
366 modulates the mitochondrial redox environment to enhance oxidative damage remains
367 unclear. We demonstrate that ferrous iron exposure enhanced both mitochondrial ROS
368 production and lipid peroxidation, consistent with changes in the mitochondrial redox
369 environment playing a significant role in ferrous iron-induced pathology[49]. In support of
370 this assertion, interventions designed to either exacerbate or abolish mitochondrial ROS
371 levels increased or decreased, respectively, the ferrous iron induced pathology of both
372 WT and neuronal A β worms. Similar to redox changes, we also found that ferrous iron-
373 induced toxicity in WT and neuronal A β worms was increased or decreased by ferroptosis
374 inducers and inhibitors, respectively. Overall, our studies demonstrate that ferrous iron-
375 induced toxicity in WT and neuronal A β worms is mediated by mitochondrial dysfunction
376 leading to reduced aerobic ATP production that occurs in concert with increased oxidative
377 stress, lipid peroxidation, and ferroptosis.

378 Brains of AD patients exhibit high levels of iron relative to that of age-matched non-
379 AD individuals[50, 51]. However, it is unclear if increased brain iron levels drive AD
380 pathology. In addition, it is unknown whether AD patients are more sensitive to iron-
381 induced oxidative stress than non-AD individuals. We found that neuronal A β worms
382 exhibited increased pathology under control conditions, greater pathology following
383 exposure to a moderate level of ferrous iron (Fig. 5) and increased sensitivity to low levels

384 of ferrous iron that do not impact age-matched WT worms (Fig. 6). Thus, our studies
385 demonstrate that neuronal A β worms exhibit both a greater responsiveness and higher
386 sensitivity to ferrous iron. We further found that the increase in ferrous iron-induced
387 sensitivity of neuronal A β worms is not due to increased ferrous iron uptake (Fig. 6C), but
388 rather due to an increase in susceptibility to ferrous iron-induced stress.

389 DMT1 (*smf-3*) facilitates cellular and mitochondrial uptake of ferrous iron[30, 52,
390 53]. Thus, we tested if DMT1 (*smf-3*) knockout in WT and neuronal A β worms would
391 provide protection against ferrous iron-induced toxicity. Importantly, DMT1 (*smf-3*)
392 knockout not only mitigated toxicity induced by ferrous iron exposure in both WT and
393 neuronal A β worms, but also reduced the basal AD pathology of neuronal A β worms. As
394 organisms age, their ability to properly handle ferrous iron weakens[3, 7, 8], which
395 explains the beneficial effects DMT1 (*smf-3*) knockout of neuronal A β worms in the
396 absence of iron exposure. Precisely how DMT1 (*smf-3*) deficiency mediates this
397 protection (e.g. via reduction of cellular iron uptake and/or reduction in mitochondrial iron
398 accumulation) will require further study. Our study revealed that increased sensitivity of
399 neuronal A β worms to properly handle ferrous iron results in pathology and that disrupting
400 ferrous iron transport in this model of AD provides protection against iron-induced
401 oxidative stress and ferroptotic cell death. Overall, our findings suggest that the energetic
402 imbalance resulting from DMT1 (*smf-3*)-dependent ferroptosis may represent an early
403 event of AD pathogenesis.

404

405 Funding

406 This work was supported by an internal University of Rochester Transition to
407 Independence Award, University of Rochester Start-up funds, and NIH-NIEHS Diversity
408 Supplement (P30 ES001247) to JOO and R01 NS092558 to APW.

409

410 Authors Contributions

411 JOO conceived and designed the study, JOO, WP, KBC carried out the experiments,
412 JOO, APW, RTD, BPL, MKO supervised the study, JOO wrote the manuscript. All
413 authors reviewed, edited, and approved the final manuscript.

414

415 Declaration of conflict of interest

416 All the authors have no conflict of interest to report

417

418 Acknowledgements

419 We thank the Center for Advanced Light Microscopy and Nanoscopy (CALMN) of the
420 University of Rochester for their technical assistance. We are grateful to Thomas Scrimale
421 of the Environmental Health Sciences Core (EHSC) for the Elemental analysis. Most of
422 the strains used in this study were obtained from the *Caenorhabditis* Genetics Center
423 (CGC), which is supported by NIH. All schematic illustrations and graphical image were
424 generated with BioRender. We appreciate the rigorous discussions and input from the
425 Mitochondrial Research & Innovation Group at University of Rochester Medical Center,

426 the Western New York Worm Group, and the Journal Club of Pharmacology and
427 Physiology Department.

428

429 Data availability

430 All data are available upon request

431

432 References

- 433 1. Crichton, R.R., D.T. Dexter, and R.J. Ward, *Brain iron metabolism and its perturbation in*
434 *neurological diseases*. J Neural Transm (Vienna), 2011. **118**(3): p. 301-14.
- 435 2. Belaidi, A.A. and A.I. Bush, *Iron neurochemistry in Alzheimer's disease and Parkinson's disease:*
436 *targets for therapeutics*. J Neurochem, 2016. **139 Suppl 1**: p. 179-197.
- 437 3. Onukwufor, J.O., R.T. Dirksen, and A.P. Wojtovich, *Iron Dysregulation in Mitochondrial*
438 *Dysfunction and Alzheimer's Disease*. Antioxidants (Basel), 2022. **11**(4).
- 439 4. Ward, R.J., et al., *The role of iron in brain ageing and neurodegenerative disorders*. Lancet
440 Neurol, 2014. **13**(10): p. 1045-60.
- 441 5. Huang, L., et al., *Intracellular amyloid toxicity induces oxytosis/ferroptosis regulated cell death*.
442 Cell Death Dis, 2020. **11**(10): p. 828.
- 443 6. Liang, Z., et al., *Natural products targeting mitochondria: emerging therapeutics for age-*
444 *associated neurological disorders*. Pharmacol Ther, 2021. **221**: p. 107749.
- 445 7. Klang, I.M., et al., *Iron promotes protein insolubility and aging in C. elegans*. Aging (Albany NY),
446 2014. **6**(11): p. 975-91.
- 447 8. Slusarczyk, P., et al., *Impaired iron recycling from erythrocytes is an early hallmark of aging*.
448 Elife, 2023. **12**.
- 449 9. Murphy, M.P., *How mitochondria produce reactive oxygen species*. Biochem J, 2009. **417**(1): p.
450 1-13.
- 451 10. Schieber, M. and N.S. Chandel, *ROS function in redox signaling and oxidative stress*. Curr Biol,
452 2014. **24**(10): p. R453-62.
- 453 11. Onukwufor, J.O., B.J. Berry, and A.P. Wojtovich, *Physiologic Implications of Reactive Oxygen*
454 *Species Production by Mitochondrial Complex I Reverse Electron Transport*. Antioxidants (Basel),
455 2019. **8**(8).
- 456 12. Onukwufor, J.O., et al., *A reversible mitochondrial complex I thiol switch mediates hypoxic*
457 *avoidance behavior in C. elegans*. Nat Commun, 2022. **13**(1): p. 2403.
- 458 13. Dixon, S.J., et al., *Ferroptosis: an iron-dependent form of nonapoptotic cell death*. Cell, 2012.
459 **149**(5): p. 1060-72.
- 460 14. Cao, J.Y. and S.J. Dixon, *Mechanisms of ferroptosis*. Cell Mol Life Sci, 2016. **73**(11-12): p. 2195-
461 209.
- 462 15. Link, C.D., *Expression of human beta-amyloid peptide in transgenic Caenorhabditis elegans*. Proc
463 Natl Acad Sci U S A, 1995. **92**(20): p. 9368-72.
- 464 16. Boyd-Kimball, D., et al., *Proteomic identification of proteins specifically oxidized in*
465 *Caenorhabditis elegans expressing human Abeta(1-42): implications for Alzheimer's disease*.
466 Neurobiol Aging, 2006. **27**(9): p. 1239-49.
- 467 17. Alexander, A.G., V. Marfil, and C. Li, *Use of Caenorhabditis elegans as a model to study*
468 *Alzheimer's disease and other neurodegenerative diseases*. Front Genet, 2014. **5**: p. 279.
- 469 18. Ewald, C.Y. and C. Li, *Understanding the molecular basis of Alzheimer's disease using a*
470 *Caenorhabditis elegans model system*. Brain Struct Funct, 2010. **214**(2-3): p. 263-83.
- 471 19. Onukwufor, J.O., et al., *Quantification of reactive oxygen species production by the red*
472 *fluorescent proteins KillerRed, SuperNova and mCherry*. Free Radic Biol Med, 2020. **147**: p. 1-7.
- 473 20. Aitken, R.J., et al., *Analysis of lipid peroxidation in human spermatozoa using BODIPY C11*. Mol
474 Hum Reprod, 2007. **13**(4): p. 203-11.
- 475 21. Farr, A.C. and M.P. Xiong, *Challenges and Opportunities of Deferoxamine Delivery for Treatment*
476 *of Alzheimer's Disease, Parkinson's Disease, and Intracerebral Hemorrhage*. Mol Pharm, 2021.
477 **18**(2): p. 593-609.


- 478 22. Garrick, M.D., et al., *DMT1: a mammalian transporter for multiple metals*. *Biometals*, 2003.
479 **16**(1): p. 41-54.
- 480 23. Salazar, J., et al., *Divalent metal transporter 1 (DMT1) contributes to neurodegeneration in*
481 *animal models of Parkinson's disease*. *Proc Natl Acad Sci U S A*, 2008. **105**(47): p. 18578-83.
- 482 24. Settivari, R., J. Levora, and R. Nass, *The divalent metal transporter homologues SMF-1/2 mediate*
483 *dopamine neuron sensitivity in caenorhabditis elegans models of manganism and parkinson*
484 *disease*. *J Biol Chem*, 2009. **284**(51): p. 35758-68.
- 485 25. Martinez-Reyes, I. and N.S. Chandel, *Mitochondrial TCA cycle metabolites control physiology and*
486 *disease*. *Nat Commun*, 2020. **11**(1): p. 102.
- 487 26. Brand, M.D. and D.G. Nicholls, *Assessing mitochondrial dysfunction in cells*. *Biochem J*, 2011.
488 **435**(2): p. 297-312.
- 489 27. Casadesus, G., et al., *Alzheimer disease: evidence for a central pathogenic role of iron-mediated*
490 *reactive oxygen species*. *J Alzheimers Dis*, 2004. **6**(2): p. 165-9.
- 491 28. Castellani, R.J., et al., *The role of iron as a mediator of oxidative stress in Alzheimer disease*.
492 *Biofactors*, 2012. **38**(2): p. 133-8.
- 493 29. Zielonka, J., J. Vasquez-Vivar, and B. Kalyanaraman, *Detection of 2-hydroxyethidium in cellular*
494 *systems: a unique marker product of superoxide and hydroethidine*. *Nat Protoc*, 2008. **3**(1): p. 8-
495 21.
- 496 30. Wolff, N.A., et al., *A role for divalent metal transporter (DMT1) in mitochondrial uptake of iron*
497 *and manganese*. *Sci Rep*, 2018. **8**(1): p. 211.
- 498 31. Trnka, J., et al., *A mitochondria-targeted nitroxide is reduced to its hydroxylamine by ubiquinol in*
499 *mitochondria*. *Free Radic Biol Med*, 2008. **44**(7): p. 1406-19.
- 500 32. Trnka, J., et al., *Antioxidant properties of MitoTEMPOL and its hydroxylamine*. *Free Radic Res*,
501 2009. **43**(1): p. 4-12.
- 502 33. Bischer, A.P., T.M. Baran, and A.P. Wojtovich, *Reactive oxygen species drive foraging decisions in*
503 *Caenorhabditis elegans*. *Redox Biol*, 2023. **67**: p. 102934.
- 504 34. Rong, Y., et al., *EUK-134, a synthetic superoxide dismutase and catalase mimetic, prevents*
505 *oxidative stress and attenuates kainate-induced neuropathology*. *Proc Natl Acad Sci U S A*, 1999.
506 **96**(17): p. 9897-902.
- 507 35. Zilka, O., et al., *On the Mechanism of Cytoprotection by Ferrostatin-1 and Liproxstatin-1 and the*
508 *Role of Lipid Peroxidation in Ferroptotic Cell Death*. *ACS Cent Sci*, 2017. **3**(3): p. 232-243.
- 509 36. Miotto, G., et al., *Insight into the mechanism of ferroptosis inhibition by ferrostatin-1*. *Redox*
510 *Biol*, 2020. **28**: p. 101328.
- 511 37. Skouta, R., et al., *Ferrostatins inhibit oxidative lipid damage and cell death in diverse disease*
512 *models*. *J Am Chem Soc*, 2014. **136**(12): p. 4551-6.
- 513 38. Yang, W.S., et al., *Regulation of ferroptotic cancer cell death by GPX4*. *Cell*, 2014. **156**(1-2): p.
514 317-331.
- 515 39. Yang, W.S. and B.R. Stockwell, *Ferroptosis: Death by Lipid Peroxidation*. *Trends Cell Biol*, 2016.
516 **26**(3): p. 165-176.
- 517 40. Forcina, G.C. and S.J. Dixon, *GPX4 at the Crossroads of Lipid Homeostasis and Ferroptosis*.
518 *Proteomics*, 2019. **19**(18): p. e1800311.
- 519 41. Sakamoto, T., et al., *Deletion of the four phospholipid hydroperoxide glutathione peroxidase*
520 *genes accelerates aging in Caenorhabditis elegans*. *Genes Cells*, 2014. **19**(10): p. 778-92.
- 521 42. Ferguson, G.D. and W.J. Bridge, *The glutathione system and the related thiol network in*
522 *Caenorhabditis elegans*. *Redox Biol*, 2019. **24**: p. 101171.
- 523 43. Herbet, S., P. Roedel-Drevet, and J.R. Drevet, *Seleno-independent glutathione peroxidases.*
524 *More than simple antioxidant scavengers*. *FEBS J*, 2007. **274**(9): p. 2163-80.

- 525 44. Wu, Y., et al., *Amyloid-beta-induced pathological behaviors are suppressed by Ginkgo biloba*
526 *extract EGb 761 and ginkgolides in transgenic Caenorhabditis elegans*. J Neurosci, 2006. **26**(50):
527 p. 13102-13.
- 528 45. Chen, L., et al., *Ablation of the Ferroptosis Inhibitor Glutathione Peroxidase 4 in Neurons Results*
529 *in Rapid Motor Neuron Degeneration and Paralysis*. J Biol Chem, 2015. **290**(47): p. 28097-28106.
- 530 46. Hambright, W.S., et al., *Ablation of ferroptosis regulator glutathione peroxidase 4 in forebrain*
531 *neurons promotes cognitive impairment and neurodegeneration*. Redox Biol, 2017. **12**: p. 8-17.
- 532 47. Smith, M.A., et al., *Iron accumulation in Alzheimer disease is a source of redox-generated free*
533 *radicals*. Proc Natl Acad Sci U S A, 1997. **94**(18): p. 9866-8.
- 534 48. Perry, G., et al., *Adventiously-bound redox active iron and copper are at the center of oxidative*
535 *damage in Alzheimer disease*. Biometals, 2003. **16**(1): p. 77-81.
- 536 49. Chen, Y., et al., *Oxidative stress induces mitochondrial iron overload and ferroptotic cell death*.
537 Sci Rep, 2023. **13**(1): p. 15515.
- 538 50. Raven, E.P., et al., *Increased iron levels and decreased tissue integrity in hippocampus of*
539 *Alzheimer's disease detected in vivo with magnetic resonance imaging*. J Alzheimers Dis, 2013.
540 **37**(1): p. 127-36.
- 541 51. LeVine, S.M., S. Tsau, and S. Gunewardena, *Exploring Whether Iron Sequestration within the CNS*
542 *of Patients with Alzheimer's Disease Causes a Functional Iron Deficiency That Advances*
543 *Neurodegeneration*. Brain Sci, 2023. **13**(3).
- 544 52. Skjorringe, T., et al., *Divalent metal transporter 1 (DMT1) in the brain: implications for a role in*
545 *iron transport at the blood-brain barrier, and neuronal and glial pathology*. Front Mol Neurosci,
546 2015. **8**: p. 19.
- 547 53. Yanatori, I. and F. Kishi, *DMT1 and iron transport*. Free Radic Biol Med, 2019. **133**: p. 55-63.

548

549

550




551

552 **Figure 1: Iron toxicity alters worm physiologic function: A)** Experimental layout showing 10 days of worm
 553 exposure to different iron doses (0, 17.5, 35, and 70 μM) at 20 $^{\circ}\text{C}$. **B)** Dose- and time-dependent effects of iron
 554 exposure on worm paralysis at 20 $^{\circ}\text{C}$. Staged L4 worms were transferred to plates containing iron (0, 17.5, 35, and 70
 555 μM). Worms were then transferred every 24 h for 10 days. Paralysis (e.g., inability to move upon stimulation) was
 556 scored every 24 h for 10 days. Data are mean \pm SEM, N=3 independent biological replicates (where one biological
 557 replicate contains 20 worms per plate). ****p<0.0001, two-way ANOVA, Tukey post hoc test. **C)** Experimental layout
 558 showing 5 days of worm exposure to iron (0 and 35 μM) at 25 $^{\circ}\text{C}$. **D)** Time course of iron exposure on worm paralysis
 559 at 25 $^{\circ}\text{C}$. Staged L4 worms were transferred to plates containing iron (0 or 35 μM). Paralysis was scored every 24 h for


560 5 days. Data are mean \pm SEM, N=5 independent biological replicates (where one biological replicate contains 20 worms
561 per plate). ns not significant, **** p <0.0001, one-way ANOVA, Tukey post hoc test. **E**). Iron reduced non-paralyzed
562 worm swimming rates at 25 °C. Staged L4 worms were transferred to plate containing iron (0 or 35 μ M). Worms were
563 then transferred every 24 h for 5 days. Non-paralyzed worms were individually transferred to plate containing 100 μ l of
564 buffer. After 30 seconds of equilibration, swimming rates were collected for 15 seconds. Data are mean \pm SEM N=5
565 independent replicates (where 4 independent worm count constitute an N). **** p <0.0001, one-way ANOVA, Tukey post
566 hoc test. Iron toxicity increases whole worm lipid peroxidation. **F**) Confocal Image and **G**) Quantification. Staged L4
567 worms were transferred to plate containing iron (0 or 35 μ M). Worms were then transferred every 24 h for 5 days. Then
568 worms were transferred to plate containing 1.25 μ M BODIPY for 60 min and prep for confocal imaging. Image scale 30
569 μ m. Data are mean \pm SEM N=5 independent replicates, ** p =0.001, one-way ANOVA, Tukey post hoc test. **H**). Total
570 iron was measured in worms using ICP-MS where dark circle (no iron) and red triangle(iron) bars treated with 35 μ M
571 iron. Data are mean \pm SEM, N=4 independent biological replicates. **** p <0.0001, Unpaired t test. **I**). Effects of
572 Deferoxamine (DFO) on iron-induced paralysis. Staged L4 worms were transferred to plates containing 0 μ M iron, 0
573 μ M iron + 100 μ M DFO 35 μ M iron and 35 μ M iron + 100 μ M DFO. Paralysis was scored every 24 h for 5 days. Data
574 are mean \pm SEM, N=5 independent biological replicates (where one biological replicate contains 20 worms per plate).
575 ns not significant, **** p <0.0001, one-way ANOVA, Tukey post hoc test. **J**). Deferoxamine restored iron-induced
576 impairment of non-paralyzed worm swimming rates. Staged L4 worms were transferred to plates containing 0 μ M iron,
577 0 μ M iron + 100 μ M DFO 35 μ M iron and 35 μ M iron + 100 μ M DFO . Non-paralyzed worms were individually transferred
578 to plate containing 100 μ l of buffer. After 30 seconds of equilibration, swimming rates were collected for 15 seconds on
579 day 5. Data are mean \pm SEM N=5 independent replicates. ns not significant, **** p <0.0001, one-way ANOVA, Tukey
580 post hoc test. **K**). DMT1 (*smf-3*) knock out abolished iron toxicity mediated worm paralysis. Staged L4 worms were
581 transferred to plates containing iron WT, *smf-3* KO, WT + iron (35 μ M) and *smf-3* KO + iron (35 μ M). Paralysis was
582 scored every 24 h for 5 days. Data are mean \pm SEM, N=3 independent biological replicates (where one biological
583 replicate contains 20 worms per plate). * p <0.05, **** p <0.0001, one-way ANOVA, Tukey post hoc test. **L**). DMT1 (*smf-*
584 *3*) knock out shielded worms from iron-induced reduction of non-paralyzed worm swimming rates. Staged L4 worms
585 were transferred to plates containing iron WT, *smf-3* KO, WT + iron (35 μ M) and *smf-3* KO + iron (35 μ M). Non-
586 paralyzed worms were individually transferred to plate containing 100 μ l of buffer. After 30 seconds of equilibration,
587 swimming rates were collected for 15 seconds. Data are mean \pm SEM N=3 independent replicates (where 4 independent
588 worm count constitute an N). ns not significant, *** p =0.0001, **** p <0.0001, one-way ANOVA, Tukey post hoc test.

589




591 **Figure 2: Iron toxicity impairs mitochondrial function and increases ROS production.** Synchronized
592 worms (0.25 million/plate) were transferred to plate with or without iron (0 and 35 μM). Mitochondria were isolated after
593 3 days and quantified for: **A**). State 3 respiration is the maximum respiratory rates following addition of ATP. Data are
594 mean \pm SEM N=3 independent replicates. * p <0.05, Unpaired t test. **B**). State 4 respiration is the minimum respiratory
595 rates upon depletion of ATP. Data are mean \pm SEM N=3 independent replicates. ns not significant, Unpaired t test. **C**).
596 Respiratory control ratio (RCR) which is the ratio of maximum respiration state 3 over that of minimum respiration state
597 4. Data are mean \pm SEM N=3 independent replicates. ** p <0.001, Unpaired t test. **D**). Iron toxicity reduced mitochondrial
598 complex I enzyme activity. Data are mean \pm SEM N=3 independent replicates. * p <0.05, Unpaired t test. **E**). Iron toxicity
599 reduced citrate synthase activity. Data are mean \pm SEM N=3 independent replicates. * p <0.0001, Unpaired t test. **F**).
600 Iron toxicity increased mitochondrial Superoxide ($\text{O}_2^{\bullet-}$) production. Data are mean \pm SEM N=7 independent replicates.
601 *** p =0.0001, Unpaired t test. **G**). DMT1 (*smf-3*) knock out reduced mitochondrial iron uptake. Mitochondrial iron was
602 measured using ICP-MS in isolated mitochondrial from WT, WT + 35 μM iron, *smf-3* KO, and *smf-3* + 35 μM iron. Data
603 are mean \pm SEM, N=3 independent biological replicates. ns not significant, *** p =0.0001, *** p <0.0001, one-way ANOVA,
604 Tukey post hoc test. **H**). DMT1 (*smf-3*) knock out abolished iron induced increase in mitochondrial calcium uptake.
605 Mitochondrial Ca was measured using ICP-MS in isolated mitochondrial from WT, WT + 35 μM iron, *smf-3* KO, and
606 *smf-3* + 35 μM iron. Data are mean \pm SEM, N=3 independent biological replicates. ns not significant, * p <0.05, ** p <0.001,
607 *** p <0.0001, one-way ANOVA, Tukey post hoc test. **I**). Mitochondrial Zn is not impacted by iron toxicity in DMT1 knock
608 out. Mitochondrial Zn was measured using ICP-MS in isolated mitochondrial from WT, WT + 35 μM iron, *smf-3* KO,
609 and *smf-3* + 35 μM iron. Data are mean \pm SEM, N=3 independent biological replicates. ns not significant, * p <0.05,
610 ** p <0.001, one-way ANOVA, Tukey post hoc test. **J**). Mitochondrial Cu is not impacted by iron toxicity in DMT1 knock.
611 Mitochondrial Cu was measured using ICP-MS in isolated mitochondrial from WT, WT + 35 μM iron, *smf-3* KO, and
612 *smf-3* + 35 μM iron. Data are mean \pm SEM, N=3 independent biological replicates. ns not significant, *** p <0.0001, one-
613 way ANOVA, Tukey post hoc test. **K**). No effect of iron on mitochondrial Mn in DMT1 knock. Mitochondrial Mn was
614 measured using ICP-MS in isolated mitochondrial from WT, WT + 35 μM iron, *smf-3* KO, and *smf-3* + 35 μM iron. Data
615 are mean \pm SEM, N=3 independent biological replicates. ns not significant, *** p =0.0001, one-way ANOVA, Tukey post
616 hoc test.

617



619 **Figure 3: Iron toxicity modulates mitochondrial redox environment. A).** Schematic diagram showing
620 specific target of mitoTempo in redox environment. **B).** MitoTempo ameliorates iron toxicity induced increase in worm
621 paralysis. Staged L4 worms were transferred to plates containing 0 μM iron, 0 μM iron + 10 μM MitoTempo, 35 μM iron
622 and 35 μM iron + 10 μM MitoTempo. Paralysis was scored every 24 h for 5 days. Data are mean \pm SEM, N=5
623 independent biological replicates (where one biological replicate contains 20 worms per plate). *** $p=0.0001$,
624 **** $p<0.0001$, one-way ANOVA, Tukey post hoc test. **C).** MitoTempo restored non-paralyzed worm swimming rates in
625 iron toxicity environment. Staged L4 worms were transferred to plates containing 0 μM iron, 0 μM iron + 10 μM
626 MitoTempo, 35 μM iron and 35 μM iron + 10 μM MitoTempo. Non-paralyzed worms were individually transferred to
627 plate containing 100 μl of buffer. After 30 seconds of equilibration, swimming rates were collected for 15 seconds. Data
628 are mean \pm SEM N=5 independent replicates (where 4 independent worm count constitute an N). ns not significant,
629 ** $p<0.001$, **** $p<0.0001$, one-way ANOVA, Tukey post hoc test. **D).** Schematic diagram showing specific target of
630 SOD mimetic manganese porphyrin [Mn(III)PyP] in redox environment. **E).** Mn(III)PyP exacerbates iron toxicity induced
631 increase in worm paralysis. Staged L4 worms were transferred to plates containing 0 μM iron, 0 μM iron + 100 μM
632 Mn(III)PyP, 35 μM iron and 35 μM iron + 100 μM Mn(III)PyP. Paralysis was scored every 24 h for 5 days. Data are
633 mean \pm SEM, N=5 independent biological replicates (where one biological replicate contains 20 worms per plate).
634 **** $p<0.0001$, one-way ANOVA, Tukey post hoc test. **F).** Mn(III)PyP worsen non-paralyzed worm swimming rates in
635 iron toxicity environment. Staged L4 worms were transferred to plates containing 0 μM iron, 0 μM iron + 100 μM
636 Mn(III)PyP, 35 μM iron and 35 μM iron + 100 μM Mn(III)PyP. Non-paralyzed worms were individually transferred to
637 plate containing 100 μl of buffer. After 30 seconds of equilibration, swimming rates were collected for 15 seconds. Data
638 are mean \pm SEM N=5 independent replicates (where 4 independent worm count constitute an N). **** $p<0.0001$, one-
639 way ANOVA, Tukey post hoc test. **G).** Schematic diagram showing specific target of EUK 134 (SOD and Catalase
640 mimetic) in mitochondrial redox environment. **H).** EUK 134 protects against iron-induced toxicity induced in worm
641 paralysis. Staged L4 worms were transferred to plates containing 0 μM iron, 0 μM iron + 100 μM EUK 134, 35 μM iron
642 and 35 μM iron + 100 μM EUK 134. Paralysis was scored every 24 h for 5 days. Data are mean \pm SEM, N=5 independent
643 biological replicates (where one biological replicate contains 20 worms per plate). ns not significant *** $p=0.0001$,
644 **** $p<0.0001$, one-way ANOVA, Tukey post hoc test. **I).** EUK 134 restored non-paralyzed worm swimming rates in iron
645 toxicity environment. Staged L4 worms were transferred to plates containing 0 μM iron, 0 μM iron + 100 μM EUK 134,
646 35 μM iron and 35 μM iron + 100 μM EUK 134. Non-paralyzed worms were individually transferred to plate containing
647 100 μl of buffer. After 30 seconds of equilibration, swimming rates were collected for 15 seconds. Data are mean \pm SEM
648 N=5 independent replicates (where 4 independent worm count constitute an N). ns not significant, ** $p<0.001$,
649 **** $p<0.0001$, one-way ANOVA, Tukey post hoc test. **J).** Schematic diagram showing specific target of N-Acetyl
650 Cysteine (NAC) in mitochondrial redox environment. **K).** NAC protects against iron toxicity induced increase in worm
651 paralysis. Staged L4 worms were transferred to plates containing 0 μM iron, 0 μM iron + 2.5 mM NAC, 35 μM iron and
652 35 μM iron + 2.5 mM NAC. Paralysis was scored every 24 h for 5 days. Data are mean \pm SEM, N=5 independent
653 biological replicates (where one biological replicate contains 20 worms per plate). * $p<0.05$, *** $p=0.0001$, **** $p<0.0001$,
654 one-way ANOVA, Tukey post hoc test. **L).** NAC restored non-paralyzed worm swimming rates in iron toxicity
655 environment. Staged L4 worms were transferred to plates containing 0 μM iron, 0 μM iron + 2.5 mM NAC, 35 μM iron
656 and 35 μM iron + 2.5 mM NAC. Non-paralyzed worms were individually transferred to plate containing 100 μl of buffer.
657 After 30 seconds of equilibration, swimming rates were collected for 15 seconds. Data are mean \pm SEM N=5
658 independent replicates (where 4 independent worm count constitute an N). ns not significant, **** $p<0.0001$, one-way
659 ANOVA, Tukey post hoc test

660




661

662 **Figure 4: Ferroptosis modulates iron induced toxicity. A)** Schematic diagram showing side of ferroptotic
663 drug target regulating iron toxicity. **B)** Ferrostatin-1 (Fer-1) ameliorates iron-induced worm paralysis. Staged L4 worms
664 were transferred to plates containing 0 μM iron, 0 μM iron + 5 μM Fer-1, 35 μM iron and 35 μM iron + 5 μM Fer-1.
665 Paralysis was scored every 24 h for 5 days. Data are mean \pm SEM, N=5 independent biological replicates (where one
666 biological replicate contains 20 worms per plate). **** p <0.0001, one-way ANOVA, Tukey post hoc test. **C)** Ferrostatin-
667 1 restored non-paralyzed worm swimming rates in iron toxicity environment. Staged L4 worms were transferred to
668 plates containing 0 μM iron, 0 μM iron + 5 μM Fer-1, 35 μM iron and 35 μM iron + 5 μM Fer-1. Non-paralyzed worms
669 were individually transferred to plate containing 100 μl of buffer. After 30 seconds of equilibration, swimming rates were
670 collected for 15 seconds. Data are mean \pm SEM N=5 independent replicates (where 4 independent worm count
671 constitute an N). ns not significant, **** p <0.0001, one-way ANOVA, Tukey post hoc test. **D)** RSL3 exacerbates iron
672 toxicity induced increase in worm paralysis. Staged L4 worms were transferred to plates containing 0 μM iron, 0 μM
673 iron + 5 nM RSL3, 0 μM iron + 5 nM RSL3 + 5 μM Fer-1, 35 μM iron, 35 μM iron + 5 nM RSL3, and 35 μM iron + 5 nM
674 RSL3 + 5 μM Fer-1. Paralysis was scored every 24 h for 5 days. Data are mean \pm SEM, N=5 independent biological
675 replicates (where one biological replicate contains 20 worms per plate). **** p <0.0001, one-way ANOVA, Tukey post
676 hoc test. **E)** RSL3 worsen non-paralyzed worm swimming rates in iron toxicity environment. Staged L4 worms were
677 transferred to plates containing 0 μM iron, 0 μM iron + 5 nM RSL3, 0 μM iron + 5 nM RSL3 + 5 μM Fer-1, 35 μM iron,
678 35 μM iron + 5 nM RSL3, and 35 μM iron + 5 nM RSL3 + 5 μM Fer-1. Non-paralyzed worms were individually transferred
679 to plate containing 100 μl of buffer. After 30 seconds of equilibration, swimming rates were collected for 15 seconds.

680 Data are mean \pm SEM N=5 independent replicates (where 4 independent worm count constitute an N). ****p<0.0001,
681 one-way ANOVA, Tukey post hoc test


682

683



685 **Figure 5: Iron toxicity exacerbates ROS and ferroptosis dependent phenotypes in neuronal A β**
686 **pathology: A)** Iron toxicity potentiate A β increased worm paralyses. Staged L4 worms (WT and neuronal A β) were
687 transferred to plates containing iron (0 or 35 μ M). Paralysis was scored every 24 h for 5 days. Data are mean \pm SEM,
688 N=5 independent biological replicates (where one biological replicate contains 20 worms per plate). ns not significant,
689 ****p<0.0001, one-way ANOVA, Tukey post hoc test. **B)** Iron toxicity worsen A β decreased in worm swimming rates.
690 Staged L4 worms (WT and neuronal A β) were transferred to plate containing iron (0 or 35 μ M). Worms were then
691 transferred every 24 h for 5 days. Non-paralyzed worms were individually transferred to plate containing 100 μ l of
692 buffer. After 30 seconds of equilibration, swimming rates were collected for 15 seconds. Data are mean \pm SEM N=5
693 independent replicates (where 4 independent worm count constitute an N). ****p<0.0001, one-way ANOVA, Tukey
694 post hoc test. **C)** Iron toxicity induced ROS potentiates A β paralyses. Staged L4 worms neuronal A β were transferred
695 to plates containing iron (0 or 35 μ M) with oxidative stress modulators 10 μ M MitoTempo, 100 μ M Mn(III)PyP, 100 μ M
696 EUK 134 and 2.5 mM NAC. Paralysis was scored every 24 h for 3 days. Data are mean \pm SEM, N=3 independent
697 biological replicates (where one biological replicate contains 20 worms per plate). ****p<0.0001, one-way ANOVA,
698 Tukey post hoc test. **D)** Impact of iron-induced ROS on neuronal A β worm swimming rates. Staged L4 worms
699 neuronal A β were transferred to plates containing iron (0 or 35 μ M) with oxidative stress modulators 10 μ M
700 MitoTempo, 100 μ M Mn(III)PyP, 100 μ M EUK 134 and 2.5 mM NAC. Worms were then transferred every 24 h for 3
701 days. Non-paralyzed worms were individually transferred to plate containing 100 μ l of buffer. After 30 seconds of
702 equilibration, swimming rates were collected for 15 seconds. Data are mean \pm SEM N=3 independent replicates
703 (where 4 independent worm count constitute an N). ns not significant, *p<0.05, **p<0.001, ***p=0.0001, ****p<0.0001,
704 one-way ANOVA, Tukey post hoc test. **E)** Ferroptosis regulates iron-induced paralysis in neuronal A β pathology.
705 Staged L4 worms neuronal A β were transferred to plates containing iron (0 or 35 μ M) ferroptosis modulators 5 nM
706 RSL3 and 5 μ M Fer-1. Paralysis was scored every 24 h for 3 days. Data are mean \pm SEM, N=5 independent
707 biological replicates (where one biological replicate contains 20 worms per plate). ns not significant, ****p<0.0001,
708 one-way ANOVA, Tukey post hoc test. **F)** Ferroptosis drives iron-induced slow swimming of neuronal A β worms.
709 Staged L4 worms neuronal A β were transferred to plates containing iron (0 or 35 μ M) ferroptosis modulators 5 nM
710 RSL3 and 5 μ M Fer-1. Worms were then transferred every 24 h for 3 days. Non-paralyzed worms were individually
711 transferred to plate containing 100 μ l of buffer. After 30 seconds of equilibration, swimming rates were collected for
712 15 seconds. Data are mean \pm SEM N=5 independent replicates (where 4 independent worm count constitute an N).
713 ns not significant, ****p<0.0001, one-way ANOVA, Tukey post hoc test.

714




715

716 **Figure 6: DMT1(*smf-3*) KO protects against neuronal Aβ pathology:** Neuronal Aβ worms exhibit increase
 717 sensitivity to iron toxicity than WT. **A)** Paralysis: Staged L4 worms (WT and neuronal Aβ) were transferred to plates
 718 containing iron (0 or 8.75 μM). Paralysis was scored every 24 h for 5 days. Data are mean ±SEM, N=5 independent
 719 biological replicates (where one biological replicate contains 20 worms per plate). ns not significant, ****p<0.0001, one-
 720 way ANOVA, Tukey post hoc test. **B)** Non-paralyzed worm swimming rates. Staged L4 worms (WT and neuronal Aβ)
 721 were transferred to plate containing iron (0 or 8.75 μM). Worms were then transferred every 24 h for 5 days. Non-
 722 paralyzed worms were individually transferred to plate containing 100 μl of buffer. After 30 seconds of equilibration,
 723 swimming rates were collected for 15 seconds. Data are mean ±SEM N=5 independent replicates (where 4 independent
 724 worm count constitute an N). ns not significant, ****p<0.0001, one-way ANOVA, Tukey post hoc test. **C)** Neuronal Aβ
 725 iron sensitivity not mediated by iron burden. Tissue iron burden was measured in WT and Aβ treated with 8.75 μM iron
 726 for 5 days using ICP-MS. Data are mean ±SEM, N=3 independent biological replicates. ns not significant, Unpaired t
 727 test. **D)** Knock out of *smf-3* in neuronal Aβ worms abolished paralysis. Staged L4 worms (neuronal Aβ and neuronal
 728 Aβ+ *smf-3* KO) were transferred to plates containing iron (0 or 35 μM). Paralysis was scored every 24 h for 5 days.

729 Data are mean \pm SEM, N=5 independent biological replicates (where one biological replicate contains 20 worms per
730 plate). ***p=0.0001, ****p<0.0001, one-way ANOVA, Tukey post hoc test. **E**) *smf-3* KO in neuronal A β worms protects
731 against A β decreased swimming rate. Staged L4 worms (neuronal A β and neuronal A β + *smf-3* KO) were transferred
732 to plates containing iron (0 or 35 μ M). Worms were then transferred every 24 h for 5 days. Non-paralyzed worms were
733 individually transferred to plate containing 100 μ l of buffer. After 30 seconds of equilibration, swimming rates were
734 collected for 15 seconds. Data are mean \pm SEM N=5 independent replicates (where 4 independent worm count
735 constitute an N). **p<0.001, ***p=0.0001, ****p<0.0001, one-way ANOVA, Tukey post hoc test.

736



737

738 Graphical abstract